Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center, Open Label, Uncontrolled, Phase IIA Clinical Trial Evaluating the Safety and Efficacy of NOX A12 in Combination With a Background Therapy of Bortezomib and Dexamethasone (VD) in Previously Treated Patients With Multiple Myeloma (MM)

NCT01521533 is registered in ClinicalTrials.gov with TME Pharma AG as lead sponsor.

NCT NCT01521533
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01521533 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center, Open Label, Uncontrolled, Phase IIA Clinical Trial Evaluating the Safety and Efficacy of NOX A12 in Combination With a Background Therapy of Bortezomib and Dexamethasone (VD) in Previously Treated Patients With Multiple Myeloma (MM)
Lead sponsor
TME Pharma AG
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2012
Completion date
September 30, 2015
Enrollment
28 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma